Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P31751
UPID:
AKT2_HUMAN
Alternative names:
Protein kinase Akt-2; Protein kinase B beta; RAC-PK-beta
Alternative UPACC:
P31751; B2RBD8; Q05BV0; Q0VAN0; Q0VAN1; Q68GC0
Background:
RAC-beta serine/threonine-protein kinase, also known as Protein kinase Akt-2, plays a pivotal role in cellular processes such as metabolism, proliferation, cell survival, growth, and angiogenesis. It achieves this through the phosphorylation of various substrates, including those involved in glucose uptake and glycogen storage, thereby regulating insulin signaling and glucose homeostasis.
Therapeutic significance:
Given its critical role in insulin signaling and glucose homeostasis, AKT2 is directly implicated in Type 2 diabetes mellitus and Hypoinsulinemic hypoglycemia with hemihypertrophy. Targeting AKT2's activity or its downstream effects presents a promising avenue for developing treatments for these metabolic disorders.